

RECEIVED
CENTRAL FAX CENTER

001/025

JUL 29 2005



Vertex Pharmaceuticals Incorporated
130 Waverly Street • Cambridge, MA 02139-4242
Tel. 617.444.6100 • Fax 617.444.6483
<http://www.vpharm.com>

FAX TRANSMISSION

| | |
|---------------------|------------------------|
| To | 571-273-8300 |
| Examiner | Deborah C. Lambkin |
| Group Art Unit | 1626 |
| From | Karen E. Brown |
| Date | July 29, 2005 |
| Application No. | 10/688,613 |
| Attorney Docket No. | VPI/00-102 CON DIV3 US |
| Total Pages | 22 |

Message or Comment

If any problems occur with this fax transmittal, please call (617) 444-6168 immediately.

RECEIVED
OIP/EAP

AUG 01 2005

Rev. 3/8/05

PAGE 1/25 * RCVD AT 7/29/2005 3:55:03 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/29 * DNIS:2738300 * CSID: * DURATION (mm:ss):04-14

RECEIVED
CENTRAL FAX CENTER
JUL 29 2005


VPI/00-102 CON DIV3 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/688,613
Confirmation No.: 2448
Filing Date: October 17, 2003
Examiner: Deborah C. Lambkin
Group Art Unit: 1626
Applicants: Michael Hale et al.
For: PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF ERK

Certificate of Facsimile Transmission Under 37 CFR 1.8

I hereby certify that this correspondence and any documents referred to as attached hereto is/are being facsimile transmitted to the United States Patent and Trademark Office on July 29, 2005.



Signature

Susan Batty-Gunn

Typed or Printed Name

08/01/2005 HTECKLU1 00000011 500725 10688613

01 FC:1253 1020.00 DA

July 29, 2005
Cambridge, Massachusetts

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith: [X] a Reply to Office Action; [] a Petition for Extension of Time; [] a substitute Specification; [] a Declaration; [] a Supplemental Declaration; [] a Power of Attorney; [] an Associate Power of Attorney; [] formal drawings; [] Notice of Appeal; [] Appeal Brief; [X] Terminal Disclaimer; to be filed in the above-identified patent application.

**RECEIVED
CENTRAL FAX CENTER
JUL 29 2005**

Applicants: Michael Hale et al.
Application No.: 10/688,613

FEE FOR ADDITIONAL CLAIMS

A fee for additional claims is not required.

A fee for additional claims is required.

The additional fee has been calculated as shown below:

| CLAIMS REMAINING AFTER AMENDMENT | HIGHEST NUMBER PREVIOUSLY PAID FOR | PRESENT EXTRA | RATE | ADDITIONAL FEES |
|---|---|------------------|---------|--------------------|
| TOTAL CLAIMS 24 | 24 | * = | X \$ 50 | = \$ 0 |

| | | | | |
|-------------------------|-----|------|---------|--------|
| INDEPENDENT CLAIMS 1 | - 3 | ** = | X \$200 | = \$ 0 |
|-------------------------|-----|------|---------|--------|

| | | |
|---|---------|------|
| FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM | + \$360 | = \$ |
|---|---------|------|

* If less than 20, insert 20.

TOTAL

\$ 0

** If less than 3, insert 3.

A check in the amount of \$____ in payment of the filing fee is transmitted herewith.

Please charge \$____ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.

The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

RECEIVED
CENTRAL FAX CENTER
JUL 29 2005

004/025

Applicants: Michael Hale et al.
Application No.: 10/688,613

EXTENSION FEE

[X] The following extension is applicable to the Response filed herewith; [] \$120.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); [] \$450.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); [X] \$1,020.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); [] \$1,590.00 extension fee for response within fourth month pursuant to 37 C.F.R. § 1.136(a); [] \$2,160.00 within fifth month pursuant to 37 C.F.R. § 1.136(a).

[] A check in the amount of [] \$120.00; [] \$450.00; [] \$1,020.00; [] \$1,590.00; [] \$2,160.00 in payment of the extension fee is transmitted herewith.

[X] Please charge the extension fee in the amount of [] \$120.00; [] \$450.00; [X] \$1,020.00; [] \$1,590.00; [] \$2,160.00 to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

[X] The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

MISCELLANEOUS FEES

[] Please charge \$ _____ to Deposit Account No. 50-0725 for _____.

Respectfully submitted,

Karen E. Brown
Karen E. Brown, Reg. No. 43,866
Attorney/Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6168
Fax: (617) 444-6483

JUL 29 2005

Attorney Docket No. VPI/00-102 CON DIV3 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/688,613
Confirmation No.: 2448
Filing Date: October 17, 2003
Examiner: Deborah C. Lambkin
Group Art Unit: 1626
Applicants: Michael Hale et al.
For: PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF ERK

July 29, 2005
Cambridge, Massachusetts

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND REPLY TO OFFICE ACTION

Sir:

This is in response to the January 31, 2005 Office Action in the above-identified application. Applicants have concurrently herewith submitted a petition to extend the time for a reply by three month(s), up to and including July 31, 2005, and have authorized the Director to charge to Deposit Account No. 50-0725 the applicable fee under 37 C.F.R. § 1.17(a)(3). Consequently, this reply is timely submitted.

Amendments to the claims begin on page 2 of this Reply.

Remarks begin at page 12 of this Reply.

Rev. 3/8/05